The deal is the largest acquisition of a U.S. target company in 2020 and comes amid AstraZeneca’s race to develop a COVID-19 vaccine.
December 12, 2020 at 02:39 PM
1 minute read
A massive $39 billion acquisition by AstraZeneca of Boston-based Alexion Pharmaceuticals was announced Saturday morning, marking the largest tie-up of the year by dollar amount involving a U.S.-based target.
The companies called on several of the most seasoned M&A lawyers across three elite firms to get the terms inked.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Honoring outstanding legal achievements focused at the national level, largely around Big Law and in-house departments.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
The American Lawyer provides the most informed and trusted source of news, data, analysis and forecasting on the global business of law.
AstraZeneca
